These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22080998)

  • 1. Gait variability in Parkinson's disease: influence of walking speed and dopaminergic treatment.
    Bryant MS; Rintala DH; Hou JG; Charness AL; Fernandez AL; Collins RL; Baker J; Lai EC; Protas EJ
    Neurol Res; 2011 Nov; 33(9):959-64. PubMed ID: 22080998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gait variability in Parkinson's disease: levodopa and walking direction.
    Bryant MS; Rintala DH; Hou JG; Collins RL; Protas EJ
    Acta Neurol Scand; 2016 Jul; 134(1):83-6. PubMed ID: 26399376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locomotor response to levodopa in fluctuating Parkinson's disease.
    Moore ST; MacDougall HG; Gracies JM; Ondo WG
    Exp Brain Res; 2008 Feb; 184(4):469-78. PubMed ID: 17828529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of levodopa on forward and backward gait patterns in persons with Parkinson's disease.
    Bryant MS; Rintala DH; Hou JG; Lai EC; Protas EJ
    NeuroRehabilitation; 2011; 29(3):247-52. PubMed ID: 22142758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting dopa-sensitive and dopa-resistant gait dysfunction in Parkinson's disease: selective responses to internal and external cues.
    Rochester L; Baker K; Nieuwboer A; Burn D
    Mov Disord; 2011 Feb; 26(3):430-5. PubMed ID: 21462258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gait stride-to-stride variability and foot clearance pattern analysis in Idiopathic Parkinson's Disease and Vascular Parkinsonism.
    Ferreira F; Gago MF; Bicho E; Carvalho C; Mollaei N; Rodrigues L; Sousa N; Rodrigues PP; Ferreira C; Gama J
    J Biomech; 2019 Jul; 92():98-104. PubMed ID: 31182234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa.
    Schaafsma JD; Giladi N; Balash Y; Bartels AL; Gurevich T; Hausdorff JM
    J Neurol Sci; 2003 Aug; 212(1-2):47-53. PubMed ID: 12809998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recuperation of slow walking in de novo Parkinson's disease is more closely associated with increased cadence, rather than with expanded stride length.
    Kwon KY; Lee HM; Kang SH; Pyo SJ; Kim HJ; Koh SB
    Gait Posture; 2017 Oct; 58():1-6. PubMed ID: 28692855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dopaminergic therapy on locomotor adaptation and adaptive learning in persons with Parkinson's disease.
    Roemmich RT; Hack N; Akbar U; Hass CJ
    Behav Brain Res; 2014 Jul; 268():31-9. PubMed ID: 24698798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
    O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ
    Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral coordination of walking and freezing of gait in Parkinson's disease.
    Plotnik M; Giladi N; Hausdorff JM
    Eur J Neurosci; 2008 Apr; 27(8):1999-2006. PubMed ID: 18412621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability of the non-instrumented walk test in persons with Parkinson's disease.
    Bryant MS; Rintala DH; Hou JG; Protas EJ
    Disabil Rehabil; 2013 Apr; 35(7):538-42. PubMed ID: 22889283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities in the stride length-cadence relation in parkinsonian gait.
    Morris M; Iansek R; Matyas T; Summers J
    Mov Disord; 1998 Jan; 13(1):61-9. PubMed ID: 9452328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait.
    Hausdorff JM; Schaafsma JD; Balash Y; Bartels AL; Gurevich T; Giladi N
    Exp Brain Res; 2003 Mar; 149(2):187-94. PubMed ID: 12610686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability in spatiotemporal gait characteristics over the course of the L-dopa cycle in people with advanced Parkinson disease .
    MacKay-Lyons M
    Phys Ther; 1998 Oct; 78(10):1083-94. PubMed ID: 9781702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone.
    Shan DE; Lee SJ; Chao LY; Yeh SI
    Can J Neurol Sci; 2001 Feb; 28(1):70-5. PubMed ID: 11252300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gait Characteristics under Imposed Challenge Speed Conditions in Patients with Parkinson's Disease During Overground Walking.
    Lee M; Youm C; Noh B; Park H; Cheon SM
    Sensors (Basel); 2020 Apr; 20(7):. PubMed ID: 32290054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy.
    Stuart S; Morris R; Giritharan A; Quinn J; Nutt JG; Mancini M
    Mov Disord; 2020 Nov; 35(11):2019-2027. PubMed ID: 32830901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease.
    Bastian AJ; Kelly VE; Perlmutter JS; Mink JW
    Mov Disord; 2003 Sep; 18(9):1008-17. PubMed ID: 14502668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Objective outcome criteria in trials of anti-parkinsonian therapy in the elderly: sensitivity, specificity and reliability of measures of brady- and hypo-kinesia.
    Bowes SG; Clark PK; Charlett A; O'Neill CJ; Leeman AL; Weller C; Nicholson PW; Deshmukh AA; Dobbs SM; Dobbs RJ
    Br J Clin Pharmacol; 1991 Mar; 31(3):295-304. PubMed ID: 2054270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.